Company Encyclopedia
View More
name
IMEIK
300896.SZ
Imeik Technology Development Co.,Ltd. engages in the research and development, production, and transformation of biomedical soft tissue repair materials in China. The company offers aesthetic medicine products, including cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere, poly facial implant thread, medical sodium hyaluronate-hydroxypropyl methylcellulose gel, sodium hyaluronate composite solution for injection, modified sodium hyaluronate gel for injection, and medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel. It also provides skin care products.
1.565 T
300896.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking19/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.77%A
    • Profit Margin58.26%A
    • Gross Margin93.24%A
  • Growth ScoreD
    • Revenue YoY-18.20%E
    • Net Profit YoY-27.66%D
    • Total Assets YoY9.68%B
    • Net Assets YoY5.26%B
  • Cash ScoreD
    • Cash Flow Margin171.64%C
    • OCF YoY-18.20%E
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreA
    • Gearing Ratio8.20%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Imeik Technology Development Q3 Net Profit Down 34.6% Y/Y

    Imeik Technology Development Co Ltd :Q3 NET PROFIT DOWN 34.6% Y/Y

    Reuters·
    SZ
    300896
    -1.14%
    Reuters·
    SZ
    300896
    -1.14%

    IMEIK: Subsidiary obtains Minoxidil topical solution "Drug Registration Certificate"

    IMEIK's wholly-owned subsidiary, Beijing Nuobote Biotechnology Co., Ltd., recently obtained the "Drug Registration Certificate" for Minoxidil topical solution approved by the National Medical Products Administration. This medication is available in two specifications: 2% and 5%, primarily used for the treatment of androgenetic alopecia and alopecia areata. Minoxidil is a peripheral vasodilator that can stimulate hair growth with long-term use

    Zhitong·
    SZ
    300896
    -1.14%
    Zhitong·
    SZ
    300896
    -1.14%

    IMEIK has established a technology development company in Tianjin

    According to the Tianyancha App, on September 24th, Tianjin IMEIK Technology Development Co., Ltd. was established, with Huang Weijun as the legal representative, a registered capital of 100,000 RMB, and a business scope that includes engineering and technology research and experimental development, medical research and experimental development, new material technology research and development, non-residential real estate leasing, cosmetics wholesale, cosmetics retail, information technology consulting services, drug production, and commissioned drug production, among others. Shareholder information shows that the company is wholly owned by IMEIK

    Zhitong·
    SZ
    300896
    -1.14%
    Zhitong·
    SZ
    300896
    -1.14%

    IMEIK: Acquisition of controlling stake in South Korea's REGEN Biotech, Inc. has been completed

    IMEIK announced that on September 10, 2025, its wholly-owned subsidiary IMEIK Hong Kong, together with Aisheng Shourui Limited, established IMEIK International and completed the acquisition of 85% of the shares of South Korea's REGEN Biotech, Inc. for USD 190 million in cash. As of the date of this announcement, the transaction has been fully settled, and the company has effectively obtained 59.5% of the shares of REGEN in South Korea. This acquisition is beneficial for the company to expand its international market and enhance its future profitability and core competitiveness

    Zhitong·
    SZ
    300896
    -1.14%
    Zhitong·
    SZ
    300896
    -1.14%

    IMEIK: The production capacity of REGEN's new factory in South Korea is steadily increasing

    IMEIK stated on the interactive platform that the overseas sales products of REGEN Company currently include two products: AestheFill and PowerFill. Since the new factory of REGEN Company in South Korea began production, the output has been steadily increasing

    Wallstreetcn·
    SZ
    300896
    -1.14%
    Wallstreetcn·
    SZ
    300896
    -1.14%
    © 2025 Longbridge｜Disclaimer